A brief recap of Diagnostics news the week of Feb 15, 2019: SpeeDX, Translational Software, PWN Health & Allscripts Healthcare Solutions, Immunovia, Curculogene, Fujirebio Diagnostics, Precipio
In a filing with the US Securities and Exchange Commission this week, Precipio said that it amended and restated an earlier securities purchase agreement with investors, The amendment enables it to issue up to $1.3 million of additional notes with applicable warrants, based on substantially the same terms and conditions as the notes and warrants granted in connection with the prior securities purchase agreement.
The revenue growth was fueled by continued volume increases in Precipio's pathology services unit, which benefited from a recently expanded sales team.
The company had been warned in March that it failed to meet a listing requirement calling for a minimum $1 per share closing price of its common stock.
